University of Cambridge spin-out DeepMirror have launched an Early Access Programme using AI-driven research to help aid new drug discovery.
Their intuitive design software was successfully tested by chemists over several months, and enables users to tap into AI-driven insights to aid molecular design throughout the drug discovery process.
DeepMirror says that its secure and user-friendly interface will make AI-powered drug discovery as simple as using a spreadsheet, ‘fast-tracking’ the whole process.
AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for drug discovery. However, this approach requires extensive liaison between the two parties, resulting in long waiting times and large amounts of resources on both sides.
DeepMirror aims to solve this issue by enabling R&D teams to carry out AI-driven research from day one, with seamless workflow integration and without the need to engage external stakeholders, develop internal teams or software, or relinquish any intellectual property.
Laboratory results can be used to refine predictions and generate novel drug candidates for further experimentation, ultimately accelerating the drug discovery process by up to four times, as estimated by the Wellcome Trust and the Boston Consulting Group1.
Dr Max Jakobs, co-founder and CEO of DeepMirror, said, “Our mission is to make AI-powered drug design as simple as browsing the web. After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.
“We are inviting researchers to get in touch to use our secure and user-friendly AI platform for drug design. DeepMirror was already used on active drug discovery programmes and led to the discovery of novel lead series and inspired the synthesis of novel compounds.”
Dr Andrew McTeague, Senior Scientist, Medicinal Chemistry at Morphic Therapeutic, added, “DeepMirror is a huge step forward in the democratisation of machine learning models and their application in drug discovery.
“Its user-friendly interface enables medicinal chemists of all levels to deploy this powerful approach in a fraction of the time. The ability to apply DeepMirror’s platform to any desired endpoint, whether it be potency, selectivity, or even ADME properties, empowers its users to make more informed decisions and to do so faster. We’re always looking for new tools to improve the efficiency of our DMTA cycles and DeepMirror helps ensure that no stone is left unturned.”
To join the waitlist for the Early Access Programme, sign up here.
1. Unlocking the potential of AI in Drug Discovery.